Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
about
Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experienceQuality of Life in elderly patients with cancerAdjuvant Systemic Therapy in Older Breast Cancer Women: Can We Optimize the Level of Care?Optimal management of breast cancer in the elderly patient: current perspectivesOptimal management of the elderly patient with head and neck cancer: Issues regarding surgery, irradiation and chemotherapyAttenuation of doxorubicin-induced cardiotoxicity by mdivi-1: a mitochondrial division/mitophagy inhibitorPreliminary Development and Evaluation of an Algorithm to Identify Breast Cancer Chemotherapy Toxicities Using Electronic Medical Records and Administrative Data.Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancerDose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy.Development and evaluation of a decision aid on mammography screening for women 75 years and olderUrban-Rural Variations in Quality-of-Life in Breast Cancer Survivors Prescribed Endocrine Therapy.Efficacy of chemotherapy in elderly patients with unresectable pancreatic cancer: a multicenter review of 895 patientsBreast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physicians.Age disparity in the dissemination of imatinib for treating chronic myeloid leukemiaThe Role of Supportive Therapy in the Era of Modern Adjuvant Treatment - Current and Future Tools.Mammography Screening and Treatment of Breast Cancer in the ElderlyAnti-cancer effects of Kochia scoparia fruit in human breast cancer cellsManagement of breast cancer in the older woman.Risk of subsequent dementia diagnoses does not vary by types of adjuvant chemotherapy in older women with breast cancer.Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401Adjuvant therapy for women over age 65 with breast cancerAdjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trialCardiovascular complications of breast cancer therapy in older adultsLetrozole in the neoadjuvant setting: the P024 trial.Clinicopathological features and treatment sensitivity of elderly Chinese breast cancer patientsTreatment of elderly cancer patients with chemotherapy.Does chemotherapy-induced neutropaenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysis.Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.Pharmacokinetics of chemotherapy in the older patient.Tolerance to chemotherapy in elderly patients with cancer.Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trialBenefits and harms of mammography screening after age 74 years: model estimates of overdiagnosis.Prognostic impact of breast cancer subtypes in elderly patients.Treatment of breast cancer in older women.Quality of life assessment in women with breast cancer: a prospective study including hormonal therapy.Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials.The safety of chemotherapy for breast cancer patients with hepatitis C virus infection.Second non-breast primary cancer following adjuvant therapy for early breast cancer: a report from the International Breast Cancer Study Group.Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA).Effect of age on drug metabolism in women with breast cancer.
P2860
Q24792539-87942A48-C010-4D7C-AAA6-678EEF0E1EA0Q24802727-D9E48CA3-D57A-4EB7-A9DF-E818B607B132Q27025860-B7B58B34-96D6-49AD-9CF0-8D6903C9EF71Q27690879-8F8F4066-D722-4A84-A823-3379CDB67542Q28083540-9EFBEAA7-6E1B-4387-8950-3CF265FB7138Q28534483-6D49713B-F713-467A-B1FD-794EB58AC635Q30845285-AC98F2CA-E121-4E42-A49A-1049252D40FDQ33345743-F04D3F76-F4D9-4CF2-AFEB-6DF9D53550B2Q33385774-65738E2E-BBE3-49BC-BDC3-5B42AFD9719EQ33596111-36E15D8C-3820-4B43-8853-BAA188AAFC91Q33616178-5DC36F18-CD9E-4564-A86F-B38757DA4F89Q33717014-A50CB43E-47AC-4064-83D9-C8AD5C1F0DE7Q33990818-4CBF9835-92AA-4358-B9C7-ECC2D15EB2D7Q34032508-6E7A72C2-577F-4BEB-8374-3E3DB138760BQ34095827-B5B4823D-BAB2-490C-A6F7-A5FA102E45D0Q34096336-63584C99-8F0E-4F87-A6E8-47B3148FCCB0Q34304580-266FB5C2-7913-4733-B14C-62B6063A7836Q34386713-719AECBD-1BEE-4F58-983D-791B914C8517Q34815323-76DB66CD-1268-42F5-BDEA-C374E046709DQ34879258-2F736590-D88D-402A-BE38-CC65A12166CFQ35051256-15E87E09-7B4D-41B3-AC5A-8BAF2DE09EBCQ35119211-FC6EA76D-D28D-4849-BDA2-28593DD6CEBCQ35584686-E284DA72-AFA0-45CC-B3FD-E63CE1B28C9DQ36026549-9749CB9C-861C-4707-9F21-6FA81BBC7CFBQ36142395-DAA17701-BA58-4BFA-BDF3-0913224DE974Q36276360-63B9C0FE-38FD-4BA6-82D5-724081A37A11Q36610747-0A6FA8C1-B53C-44DB-BF42-6328072597B4Q36659104-4D88C23D-6B1D-4BEC-A946-9B3E2CF4D533Q36715263-DA690C7F-28D1-47D8-B00F-11677E8CB87AQ36715266-76AE14CF-40CB-435D-AB38-D14D5E952FFBQ36733078-257E189A-343A-4CDE-A785-F78FA3AFA8B9Q36770273-E8F649C1-5D53-4A95-A1FB-2DE7E0DCB2C1Q36901185-AC0A4494-442B-4DA9-AF7D-08A726F250ABQ36953425-EB26BF3C-E8ED-43D7-9E2B-E813F0DC80E1Q36998149-12070E82-564A-493D-A61F-59686A8F8515Q37038642-3FE37344-051A-4451-A028-F48AAE40ECF3Q37054066-E34BF715-6206-4675-9596-D97057AEF0D4Q37222860-5EF7B665-6596-4CE8-9578-43CDBA3B7AC4Q37301426-423AFBED-0760-469B-B3C7-97DAD3B923AFQ37325560-FF0E602C-8D20-4859-8467-44996587FF68
P2860
Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Burdens and benefits of adjuva ...... Cancer Study Group Trial VII.
@en
Burdens and benefits of adjuva ...... Cancer Study Group Trial VII.
@nl
type
label
Burdens and benefits of adjuva ...... Cancer Study Group Trial VII.
@en
Burdens and benefits of adjuva ...... Cancer Study Group Trial VII.
@nl
prefLabel
Burdens and benefits of adjuva ...... Cancer Study Group Trial VII.
@en
Burdens and benefits of adjuva ...... Cancer Study Group Trial VII.
@nl
P2093
P1476
Burdens and benefits of adjuva ...... Cancer Study Group Trial VII.
@en
P2093
A Goldhirsch
A S Coates
A Veronesi
B Thürlimann
C M Rudenstam
D Crivellari
E Simoncini
P304
P356
10.1200/JCO.2000.18.7.1412
P407
P577
2000-04-01T00:00:00Z